-
Agnolon V, Kiseljak D, Wurm MJ, Wurm FM, Foissard C, Gallais F, Wehrle S, Muñoz-Fontela C, Bellanger L, Correia BE, Corradin G, Spertini F (2020) Designs and characterization of subunit Ebola GP vaccine candidates: implications for immunogenicity. Front Immunol 11: 586595
doi: 10.3389/fimmu.2020.586595
-
Cao G, Gao X, Zhan Y, Wang Q, Zhang Z, Dimitrov DS, Gong R (2020) An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding. Mabs 12: 1689027
doi: 10.1080/19420862.2019.1689027
-
Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351: 1339–1342
doi: 10.1126/science.aad5224
-
Das DK, Bulow U, Diehl WE, Durham ND, Senjobe F, Chandran K, Luban J, Munro JB (2020) Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biol 18: e3000626
doi: 10.1371/journal.pbio.3000626
-
Davey RT, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D (2016) A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375: 1448–1456
doi: 10.1056/NEJMoa1604330
-
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E (2016) Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60: 6–13
doi: 10.1128/AAC.01802-15
-
Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). Mabs 1: 26–28
doi: 10.4161/mabs.1.1.7480
-
Duggan S (2018) Caplacizumab: First Global Approval. Drugs 78: 1639–1642
doi: 10.1007/s40265-018-0989-0
-
Emanuel J, Marzi A, Feldmann H (2018) Filoviruses: ecology, molecular biology, and evolution. Adv Virus Res 100: 189–221
-
Gao X, Conard A, Yang C, Zhan Y, Zeng F, Shi J, Li W, Dimitrov DS, Gong R (2019) Optimization of the C-terminus of an autonomous human IgG1 CH2 domain for stability and aggregation resistance. Mol Pharm 16: 3647–3656
doi: 10.1021/acs.molpharmaceut.9b00544
-
Gong R, Xiao G (2013) Engineered antibody variable and constant domains as therapeutic candidates. Pharm Pat Anal 2: 637–646
doi: 10.4155/ppa.13.44
-
Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284: 14203–14210
doi: 10.1074/jbc.M900769200
-
Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J Biol Chem 286: 27288–27293
doi: 10.1074/jbc.M111.254219
-
Gong R, Wang Y, Ying T, Dimitrov DS (2012) Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS ONE 7: e42288
doi: 10.1371/journal.pone.0042288
-
Gregory SM, Harada E, Liang B, Delos SE, White JM, Tamm LK (2011) Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci USA 108: 11211–11216
doi: 10.1073/pnas.1104760108
-
Karan LS, Makenov MT, Korneev MG, Sacko N, Boumbaly S, Yakovlev SA, Kourouma K, Bayandin RB, Gladysheva AV, Shipovalov AV, Yurganova IA, Grigorieva YE, Fedorova MV, Scherbakova SA, Kutyrev VV, Agafonov AP, Maksyutov RA, Shipulin GA, Maleev VV, Boiro M, Akimkin VG, Popova AY (2019) Bombali virus in mops condylurus bats, Guinea. Emerg Infect Dis 25: 1774–1775
-
Kazemi-Lomedasht F, Behdani M, Bagheri KP, Habibi-Anbouhi M, Abolhassani M, Arezumand R, Shahbazzadeh D, Mirzahoseini H (2015) Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Mol Immunol 65: 58–67
doi: 10.1016/j.molimm.2015.01.010
-
Keck Z-Y, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ (2016) Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol 90: 279–291
doi: 10.1128/JVI.02172-15
-
Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177–182
doi: 10.1038/nature07082
-
Markham A (2021) REGN-EB3: first approval. Drugs 81: 175–178
doi: 10.1007/s40265-020-01452-3
-
Milligan JC, Parekh DV, Fuller KM, Igarashi M, Takada A, Saphire EO (2019) Structural characterization of pan-Ebolavirus antibody 6D6 targeting the fusion peptide of the surface glycoprotein. J Infect Dis 219: 415–419
doi: 10.1093/infdis/jiy532
-
Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351: 1343–1346
doi: 10.1126/science.aad6117
-
Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, Group PW, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallee D, Nordwall J, Team PCS (2019) A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 381: 2293–2303
doi: 10.1056/NEJMoa1910993
-
Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martínez M, Herrera JE, Pizarro M, Hutchison SK, Echevarría JE, Lipkin WI, Tenorio A (2011) Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog 7: e1002304
doi: 10.1371/journal.ppat.1002304
-
Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB (2016) Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 1: 16128
doi: 10.1038/nmicrobiol.2016.128
-
Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141: 218–227
doi: 10.1016/j.clim.2011.08.008
-
Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4: 138ra181
-
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514: 47–53
doi: 10.1038/nature13777
-
Schepens B, Ibanez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X (2011) Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis 204: 1692–1701
doi: 10.1093/infdis/jir622
-
Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, Gao GF (2016) Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164: 258–268
doi: 10.1016/j.cell.2015.12.044
-
Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46: W296–W303
doi: 10.1093/nar/gky427
-
Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega M-A, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA (2017) Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169
-
Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X (2014) Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 32: 5722–5729
doi: 10.1016/j.vaccine.2014.08.028
-
Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y, Yang Z, Lu L, Jiang S, Ying T (2020) Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe 27: 891–898 e895
doi: 10.1016/j.chom.2020.04.023
-
Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 387: 387–392
doi: 10.1016/j.bbrc.2009.07.044
-
Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, Lal RB, Dimitrov DS (2004) Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 335: 209–219
doi: 10.1016/j.jmb.2003.09.055
-
Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535: 169–172
doi: 10.1038/nature18615
-
Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang C-I, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ (2017) Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169: 891–904. e15
doi: 10.1016/j.cell.2017.04.038